Northwest Voices | Letters to the Editor
Dendreon develops, proves treatment for prostate cancer
Posted by Letters editor
Health-care improvements in hands of city, state leaders
Your recent editorial on a newly approved cancer medicine developed in Washington state called for growth within the Seattle biopharmaceutical research cluster, and with good reason [“Dendreon has done it,” Opinion, May 7].
It is a highly innovative and high-growth sector. In 2006, the most recent year that data were available, the sector employed more than 21,000 jobs in the Seattle-Tacoma-Bellevue area and nearly 68,000 throughout Washington, leading to $916.5 million invested in research and development in the state.
That is why it is worth supporting public programs focused on growing this important sector. From the Life Science Delivery Fund, which provides grants to foster health-care competitiveness throughout the state, to the city-sponsored development of Seattle’s own South Lake Union district, much of the future of local biopharmaceutical businesses rests in the hands of city and state leaders.
— Ken Johnson, senior vice president of Pharmaceutical Research and Manufacturers of America, Washington, D.C.
Feb 21 - 7:00 AM Sen. Patty Murray plans to reintroduce Wild Olympics bill
Feb 21 - 7:00 AM Gun bill allows for police inspection
Feb 21 - 7:00 AM President Obama's early childhood education expansion proposal
Feb 21 - 7:00 AM Don't restrict public's right to access information
Feb 20 - 4:00 PM Lake Burien: public, but private